
What is claimed is:

1. A crystalline form of Compound A:  (Compound A).

2. The crystalline form of claim 1, wherein Compound A is in free base from.

3. The crystalline form of claim 1 or 2, as Compound A free base ("Form 1"), characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.5, 9.0, 13.3, 16.2, and 18.8 ± 0.2° 2θ using CuKα radiation.

4. The crystalline form of claim 1 or 2, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks selected from 4.5, 6.7, 9.0, 12.2, 12.5, 12.8, 13.3, 13.7, 14.3, 14.7, 15.7, 16.2, 16.7, 17.4, 17.6, 18.0, 18.4, 18.8, 19.6, 20.0, 20.3, 20.8, 21.2, 21.6, 22.2, 22.5, 23.0, 23.8, 24.1, 24.6, 25.1, 26.2, 26.4, 26.8, 27.8, 28.4, 28.8, 29.7, 30.5, 30.9, 32.7, 34.4, 35.1, 35.6, 36.4, 37.8, and 39.4 ± 0.2° 2θ using CuKα radiation.

5. The crystalline form of claim 1 or 2, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks selected from 4.5, 6.7, 9.0, 12.2, 12.5, 12.8, 13.3, 13.7, 14.3, 14.7, 15.7, 16.2, 16.7, 17.4, 17.6, 18.0, 18.4, 18.8, 19.6, 20.0, 20.3, 20.8, 21.2, 21.6, 22.2, 22.5, 23.0, 23.8, 24.1, 24.6, 25.1, 26.2, 26.4, 26.8, 27.8, 28.4, 28.8, 29.7, 30.5, 30.9, 32.7, 34.4, 35.1, 35.6, 36.4, 37.8, and 39.4 ± 0.2° 2θ using CuKα radiation.

6. The crystalline form of claim 1 or 2, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks selected from 4.5, 6.7, 9.0, 12.2, 12.5, 12.8, 13.3, 13.7, 14.3, 14.7, 15.7, 16.2, 16.7, 17.4, 17.6, 18.0, 18.4, 18.8, 19.6, 20.0, 20.3, 20.8, 21.2, 21.6, 22.2, 22.5, 23.0, 23.8, 24.1, 24.6, 25.1, 26.2, 26.4, 26.8, 27.8, 28.4, 28.8, 29.7, 30.5, 30.9, 32.7, 34.4, 35.1, 35.6, 36.4, 37.8, and 39.4 ± 0.2° 2θ using CuKα radiation.

7. The crystalline form of claim 1 or 2, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks selected from 4.5, 6.7, 9.0, 12.2, 12.5, 12.8, 13.3, 13.7, 14.3, 14.7, 15.7, 16.2, 16.7, 17.4, 17.6, 18.0, 18.4, 18.8, 19.6, 20.0, 20.3, 20.8, 21.2, 21.6, 22.2, 22.5, 23.0, 23.8, 24.1, 24.6, 25.1, 26.2, 26.4, 26.8, 27.8, 28.4, 28.8, 29.7, 30.5, 30.9, 32.7, 34.4, 35.1, 35.6, 36.4, 37.8, and 39.4 ± 0.2° 2θ using CuKα radiation.


8. The crystalline form of any one of claims 1-7, characterized by a differential scanning calorimetery (DSC) thermograph comprising an endotherm with an onset of 225 °C ± 3 °C.

9. The crystalline form of any one of claims 1-8, characterized by ^{13}C solid state NMR comprising at least three peaks selected from 39.2, 43.8, 51.6, 58.1, 65.9, 71.8, 73.6, 114.7, 120.8, 125.1, 126.1, 128.2, 130.8, 142.2, 143.3, 145.3, 148.5, 149.2, 156.9, and 169.6 ppm.

10. The crystalline form of any one of claims 1-8, characterized by ^{13}C solid state NMR comprising at least five peaks selected from 39.2, 43.8, 51.6, 58.1, 65.9, 71.8, 73.6, 114.7, 120.8, 125.1, 126.1, 128.2, 130.8, 142.2, 143.3, 145.3, 148.5, 149.2, 156.9, and 169.6 ppm.

11. The crystalline form of any one of claims 1-8, characterized by ^{13}C solid state NMR comprising at least seven peaks selected from 39.2, 43.8, 51.6, 58.1, 65.9, 71.8, 73.6, 114.7, 120.8, 125.1, 126.1, 128.2, 130.8, 142.2, 143.3, 145.3, 148.5, 149.2, 156.9, and 169.6 ppm.

12. The crystalline form of any one of claims 1-11, characterized by ^{19}F solid state NMR comprising peaks at -62.0 and -63.9 ppm.

13. An amorphous form of Compound A free base  (Compound A).

14. The amorphous form of claim 13, having a glass transition temperature (Tg) of 119 °C ± 3 °C.

15. A pharmaceutical composition comprising the crystalline form or amorphous form of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

16. The pharmaceutical composition of claim 15, wherein the composition is formulated for oral delivery.

17. The pharmaceutical composition of claim 15 or 16, wherein the composition is formulated for once-a-day administration.

18. The pharmaceutical composition of any one of claims 15-17, wherein the composition is an oral tablet.

19. The pharmaceutical composition of any one of claims 15-18, comprising 1-4000 mg of the crystalline form or amorphous form.

20. The pharmaceutical composition of claim 19 comprising 1-2000 mg of the compound or crystalline form.

21. Use of the crystalline form or amorphous form of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cancer in a subject in need thereof.

22. The use of claim 21, wherein the cancer is ovarian, lung, lymphoid, glioblastoma, colon, melanoma, gastric, pancreatic, or bladder cancer.

23. The use of claim 22, wherein the cancer is non-small cell lung cancer.

24. The use of claim 22, wherein the cancer is pancreatic cancer.

25. The use of any one of claims 21-24, wherein the cancer is a MTAP-null cancer.

26. The use of claim 25, wherein the cancer the MTAP-null cancer is selected from lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, pancreatic adenocarcinoma, gallbladder cancer, and mesothelioma.

27. The use of claim 26, wherein the MTAP-null cancer is lung cancer.

28. The use of claim 27, wherein the lung cancer is non-squamous cell lung cancer (NSCLC).

29. The use of any one of claims 21-28, wherein the cancer is not a primary brain tumor or lymphoma.

30. The use of any one of claims 21-29, wherein the subject does not have, and has not had, interstitial lung disease or pneumonitis.

31. The use of any one of claims 21-30, wherein the crystalline form is crystalline Form 1.